BioScrip, Inc. (BIOS) Holdings Increased by TIAA CREF Investment Management LLC
TIAA CREF Investment Management LLC increased its position in BioScrip, Inc. (NASDAQ:BIOS) by 11.7% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 308,042 shares of the company’s stock after purchasing an additional 32,242 shares during the period. TIAA CREF Investment Management LLC owned 0.25% of BioScrip worth $836,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of the company. Teachers Advisors LLC lifted its holdings in shares of BioScrip by 10.2% in the 2nd quarter. Teachers Advisors LLC now owns 219,040 shares of the company’s stock valued at $595,000 after purchasing an additional 20,290 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in shares of BioScrip by 50.8% in the 2nd quarter. Alliancebernstein L.P. now owns 141,900 shares of the company’s stock valued at $385,000 after purchasing an additional 47,800 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of BioScrip by 1.0% in the 2nd quarter. Wells Fargo & Company MN now owns 114,810 shares of the company’s stock valued at $312,000 after purchasing an additional 1,100 shares during the last quarter. Benchmark Capital Advisors purchased a new stake in shares of BioScrip in the 2nd quarter valued at about $391,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of BioScrip by 6.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 504,459 shares of the company’s stock valued at $1,369,000 after purchasing an additional 28,615 shares during the last quarter. 83.00% of the stock is owned by institutional investors and hedge funds.
In other BioScrip news, Director Michael G. Bronfein sold 27,000 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $2.69, for a total transaction of $72,630.00. Following the transaction, the director now owns 129,669 shares in the company, valued at approximately $348,809.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Coliseum Capital Management, L sold 886,478 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $3.08, for a total value of $2,730,352.24. The disclosure for this sale can be found here. Insiders sold a total of 3,760,419 shares of company stock worth $11,144,519 in the last 90 days. 0.80% of the stock is currently owned by insiders.
BioScrip, Inc. (NASDAQ BIOS) opened at $2.11 on Monday. BioScrip, Inc. has a 52-week low of $0.98 and a 52-week high of $3.39. The company has a debt-to-equity ratio of -6.11, a current ratio of 1.91 and a quick ratio of 1.60.
BioScrip (NASDAQ:BIOS) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.02). The company had revenue of $198.70 million during the quarter, compared to analysts’ expectations of $202.91 million. The firm’s revenue for the quarter was down 11.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.12) EPS. equities research analysts predict that BioScrip, Inc. will post -0.63 EPS for the current year.
Several research firms have recently weighed in on BIOS. Jefferies Group LLC reissued a “buy” rating and issued a $4.00 target price (up from $3.00) on shares of BioScrip in a report on Thursday, August 10th. ValuEngine cut BioScrip from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Zacks Investment Research cut BioScrip from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. BidaskClub cut BioScrip from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. Finally, SunTrust Banks, Inc. upgraded BioScrip from a “hold” rating to a “buy” rating and boosted their price target for the company from $3.25 to $3.75 in a research report on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $3.60.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.